Medicine ushered in an era of innovation!Innovative medicine ETF (159992) rose nearly 5%, Midi and Zhaoyan's new drugs led the rise

On July 4, the innovative drug sector rose for the sixth consecutive week.Nuo He Zhiyuan rose over 18%, Midicei rose more than 10%, Zhaoyan's new medicine rose daily limit, Kailei, East China Pharmaceutical, Tiger Medicine, and Jiuzhou Pharmaceutical rose by more than 7%, driving innovative medicine ETF (159992) risingNearly 5%, the current turnover has exceeded 270 million yuan.The market continues to be optimistic about the performance of the innovative drug sector. In the past 5th, the net inflow of innovation medicine ETF (159992) has a net inflow of funds of 266 million yuan.

Guosheng Securities said that innovation is the eternal main line, and medicine has ushered in an era of innovation.The current pharmaceutical risk appetite is upward. From the beginning of the medium and long -term dimension, the pharmaceutical market should focus on the contraction of the attention of the pharmaceutical market. Once the pharmaceutical style is biased, it is expected to show a state of changes in multiple segments.Innovative drugs are encouraged by policies, and some companies have entered the harvest period one after another. The definition of demand release and jumping aging for a long time is comparative.

- END -